Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

The Risk of Falsely Declaring Non-Inferiority of Novel Latent Tuberculosis Treatment in Large Trials.

Abubakar I, Cobelens FG, Rangaka MX.

Am J Respir Crit Care Med. 2019 Dec 9. doi: 10.1164/rccm.201911-2258ED. [Epub ahead of print] No abstract available.

PMID:
31816247
2.

How Well Do Routine Molecular Diagnostics Detect Rifampin Heteroresistance in Mycobacterium tuberculosis?

Ng KCS, Supply P, Cobelens FGJ, Gaudin C, Gonzalez-Martin J, de Jong BC, Rigouts L.

J Clin Microbiol. 2019 Oct 23;57(11). pii: e00717-19. doi: 10.1128/JCM.00717-19. Print 2019 Nov.

3.

BCG vaccination protects against infection with Mycobacterium tuberculosis ascertained by tuberculin skin testing.

Pelzer PT, Mutayoba B, Cobelens FGJ.

J Infect. 2018 Oct;77(4):335-340. doi: 10.1016/j.jinf.2018.03.010. Epub 2018 May 18.

PMID:
29778630
4.

Solar ultraviolet B exposure and global variation in tuberculosis incidence: an ecological analysis.

Boere TM, Visser DH, van Furth AM, Lips P, Cobelens FGJ.

Eur Respir J. 2017 Jun 15;49(6). pii: 1601979. doi: 10.1183/13993003.01979-2016. Print 2017 Jun.

5.

Tuberculosis resistance-conferring mutations with fitness cost among HIV-positive individuals in Uganda.

Ssengooba W, Lukoye D, Meehan CJ, Kateete DP, Joloba ML, de Jong BC, Cobelens FG, van Leth F.

Int J Tuberc Lung Dis. 2017 May 1;21(5):531-536. doi: 10.5588/ijtld.16.0544.

PMID:
28399968
6.

MDR-TB treatment as prevention: The projected population-level impact of expanded treatment for multidrug-resistant tuberculosis.

Kendall EA, Azman AS, Cobelens FG, Dowdy DW.

PLoS One. 2017 Mar 8;12(3):e0172748. doi: 10.1371/journal.pone.0172748. eCollection 2017.

7.

Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis.

Gomez GB, Dowdy DW, Bastos ML, Zwerling A, Sweeney S, Foster N, Trajman A, Islam MA, Kapiga S, Sinanovic E, Knight GM, White RG, Wells WA, Cobelens FG, Vassall A.

BMC Infect Dis. 2016 Dec 1;16(1):726.

8.

Individualizing management of extensively drug-resistant tuberculosis: diagnostics, treatment, and biomarkers.

Alffenaar JC, Akkerman OW, Anthony RM, Tiberi S, Heysell S, Grobusch MP, Cobelens FG, Van Soolingen D.

Expert Rev Anti Infect Ther. 2017 Jan;15(1):11-21. Epub 2016 Oct 24. Review.

PMID:
27762157
9.

Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.

Kunkel A, Cobelens FG, Cohen T.

PLoS Med. 2016 Oct 11;13(10):e1002142. doi: 10.1371/journal.pmed.1002142. eCollection 2016 Oct.

10.

Do Xpert MTB/RIF Cycle Threshold Values Provide Information about Patient Delays for Tuberculosis Diagnosis?

Ssengooba W, Respeito D, Mambuque E, Blanco S, Bulo H, Mandomando I, de Jong BC, Cobelens FG, García-Basteiro AL.

PLoS One. 2016 Sep 9;11(9):e0162833. doi: 10.1371/journal.pone.0162833. eCollection 2016.

11.

Whole genome sequencing reveals mycobacterial microevolution among concurrent isolates from sputum and blood in HIV infected TB patients.

Ssengooba W, de Jong BC, Joloba ML, Cobelens FG, Meehan CJ.

BMC Infect Dis. 2016 Aug 5;16:371. doi: 10.1186/s12879-016-1737-2.

12.

Whole genome sequencing to complement tuberculosis drug resistance surveys in Uganda.

Ssengooba W, Meehan CJ, Lukoye D, Kasule GW, Musisi K, Joloba ML, Cobelens FG, de Jong BC.

Infect Genet Evol. 2016 Jun;40:8-16. doi: 10.1016/j.meegid.2016.02.019. Epub 2016 Feb 23.

13.

The transmission of Mycobacterium tuberculosis in high burden settings.

Yates TA, Khan PY, Knight GM, Taylor JG, McHugh TD, Lipman M, White RG, Cohen T, Cobelens FG, Wood R, Moore DA, Abubakar I.

Lancet Infect Dis. 2016 Feb;16(2):227-38. doi: 10.1016/S1473-3099(15)00499-5. Epub 2016 Jan 26. Review. Erratum in: Lancet Infect Dis. 2016 Mar;16(3):279.

PMID:
26867464
14.

End TB with precision treatment!

van der Burgt EP, Sturkenboom MG, Bolhuis MS, Akkerman OW, Kosterink JG, de Lange WC, Cobelens FG, van der Werf TS, Alffenaar JW.

Eur Respir J. 2016 Feb;47(2):680-2. doi: 10.1183/13993003.01285-2015. No abstract available.

15.

Shortened first-line TB treatment in Brazil: potential cost savings for patients and health services.

Trajman A, Bastos ML, Belo M, Calaça J, Gaspar J, Dos Santos AM, Dos Santos CM, Brito RT, Wells WA, Cobelens FG, Vassall A, Gomez GB.

BMC Health Serv Res. 2016 Jan 22;16:27. doi: 10.1186/s12913-016-1269-x.

16.

High Genotypic Discordance of Concurrent Mycobacterium tuberculosis Isolates from Sputum and Blood of HIV-Infected Individuals.

Ssengooba W, Cobelens FG, Nakiyingi L, Mboowa G, Armstrong DT, Manabe YC, Joloba ML, de Jong BC.

PLoS One. 2015 Jul 15;10(7):e0132581. doi: 10.1371/journal.pone.0132581. eCollection 2015.

17.

The predictive value of current haemoglobin levels for incident tuberculosis and/or mortality during long-term antiretroviral therapy in South Africa: a cohort study.

Kerkhoff AD, Wood R, Cobelens FG, Gupta-Wright A, Bekker LG, Lawn SD.

BMC Med. 2015 Apr 2;13:70. doi: 10.1186/s12916-015-0320-9.

18.

Variation and risk factors of drug resistant tuberculosis in sub-Saharan Africa: a systematic review and meta-analysis.

Lukoye D, Ssengooba W, Musisi K, Kasule GW, Cobelens FG, Joloba M, Gomez GB.

BMC Public Health. 2015 Mar 25;15:291. doi: 10.1186/s12889-015-1614-8. Review.

19.

Resolution of anaemia in a cohort of HIV-infected patients with a high prevalence and incidence of tuberculosis receiving antiretroviral therapy in South Africa.

Kerkhoff AD, Wood R, Cobelens FG, Gupta-Wright A, Bekker LG, Lawn SD.

BMC Infect Dis. 2014 Dec 21;14:3860. doi: 10.1186/s12879-014-0702-1.

20.

The Mycobacterium tuberculosis Uganda II family and resistance to first-line anti-tuberculosis drugs in Uganda.

Ezati N, Lukoye D, Wampande EM, Musisi K, Kasule GW, Cobelens FG, Kateete DP, Joloba ML.

BMC Infect Dis. 2014 Dec 19;14:703. doi: 10.1186/s12879-014-0703-0.

21.

Clinical utility of a novel molecular assay in various combination strategies with existing methods for diagnosis of HIV-related tuberculosis in Uganda.

Ssengooba W, Nakiyingi L, Armstrong DT, Cobelens FG, Alland D, Manabe YC, Dorman SE, Ellner JJ, Joloba ML.

PLoS One. 2014 Sep 15;9(9):e107595. doi: 10.1371/journal.pone.0107595. eCollection 2014.

23.

A household survey on screening practices of household contacts of smear positive tuberculosis patients in Vietnam.

Thanh TH, Ngoc SD, Viet NN, Van HN, Horby P, Cobelens FG, Wertheim HF.

BMC Public Health. 2014 Jul 11;14:713. doi: 10.1186/1471-2458-14-713.

24.

The T2 Mycobacterium tuberculosis genotype, predominant in Kampala, Uganda, shows negative correlation with antituberculosis drug resistance.

Lukoye D, Katabazi FA, Musisi K, Kateete DP, Asiimwe BB, Okee M, Joloba ML, Cobelens FG.

Antimicrob Agents Chemother. 2014 Jul;58(7):3853-9. doi: 10.1128/AAC.02338-13. Epub 2014 Apr 28.

25.

Characterisation of Mycobacterium tuberculosis isolates lacking IS6110 in Viet Nam.

Huyen MN, Tiemersma EW, Kremer K, de Haas P, Lan NT, Buu TN, Sola C, Cobelens FG, van Soolingen D.

Int J Tuberc Lung Dis. 2013 Nov;17(11):1479-85. doi: 10.5588/ijtld.13.0149.

PMID:
24125454
26.

Epidemiology of isoniazid resistance mutations and their effect on tuberculosis treatment outcomes.

Huyen MN, Cobelens FG, Buu TN, Lan NT, Dung NH, Kremer K, Tiemersma EW, van Soolingen D.

Antimicrob Agents Chemother. 2013 Aug;57(8):3620-7. doi: 10.1128/AAC.00077-13. Epub 2013 May 20.

27.

First national tuberculin survey in Viet Nam: characteristics and association with tuberculosis prevalence.

Hoa NB, Cobelens FG, Sy DN, Nhung NV, Borgdorff MW, Tiemersma EW.

Int J Tuberc Lung Dis. 2013 Jun;17(6):738-44. doi: 10.5588/ijtld.12.0200.

PMID:
23676155
28.

For whom the bell tolls: isoniazid preventive therapy and tuberculosis drug resistance.

Cobelens FG.

Sci Transl Med. 2013 Apr 10;5(180):180fs12. doi: 10.1126/scitranslmed.3006094.

PMID:
23576813
29.

Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action.

Wells WA, Boehme CC, Cobelens FG, Daniels C, Dowdy D, Gardiner E, Gheuens J, Kim P, Kimerling ME, Kreiswirth B, Lienhardt C, Mdluli K, Pai M, Perkins MD, Peter T, Zignol M, Zumla A, Schito M.

Lancet Infect Dis. 2013 May;13(5):449-58. doi: 10.1016/S1473-3099(13)70025-2. Epub 2013 Mar 24. Review.

30.

Tuberculosis relapse in Vietnam is significantly associated with Mycobacterium tuberculosis Beijing genotype infections.

Huyen MN, Buu TN, Tiemersma E, Lan NT, Dung NH, Kremer K, Soolingen DV, Cobelens FG.

J Infect Dis. 2013 May 15;207(10):1516-24. doi: 10.1093/infdis/jit048. Epub 2013 Feb 13.

PMID:
23408848
31.

Clustering of Beijing genotype Mycobacterium tuberculosis isolates from the Mekong delta in Vietnam on the basis of variable number of tandem repeat versus restriction fragment length polymorphism typing.

Huyen MN, Kremer K, Lan NT, Buu TN, Cobelens FG, Tiemersma EW, de Haas P, van Soolingen D.

BMC Infect Dis. 2013 Feb 2;13:63. doi: 10.1186/1471-2334-13-63.

32.

Suspected tuberculosis case detection and referral in private pharmacies in Viet Nam.

Vu DH, van Rein N, Cobelens FG, Nguyen TT, Le VH, Brouwers JR.

Int J Tuberc Lung Dis. 2012 Dec;16(12):1625-9. doi: 10.5588/ijtld.12.0295.

PMID:
23131260
33.

Increased transmission of Mycobacterium tuberculosis Beijing genotype strains associated with resistance to streptomycin: a population-based study.

Buu TN, van Soolingen D, Huyen MN, Lan NT, Quy HT, Tiemersma EW, Kremer K, Borgdorff MW, Cobelens FG.

PLoS One. 2012;7(8):e42323. doi: 10.1371/journal.pone.0042323. Epub 2012 Aug 13.

34.

Yield of interview screening and chest X-ray abnormalities in a tuberculosis prevalence survey.

Hoa NB, Cobelens FG, Sy DN, Nhung NV, Borgdorff MW, Tiemersma EW.

Int J Tuberc Lung Dis. 2012 Jun;16(6):762-7. doi: 10.5588/ijtld.11.0581. Epub 2012 Apr 9.

PMID:
22507287
35.

Mixed tuberculosis infections in rural South Vietnam.

Huyen MN, Kremer K, Lan NT, Cobelens FG, Buu TN, Dung NH, Caws M, Tiemersma EW, van Soolingen D.

J Clin Microbiol. 2012 May;50(5):1586-92. doi: 10.1128/JCM.00434-12. Epub 2012 Feb 29.

36.

Health-seeking behaviour among adults with prolonged cough in Vietnam.

Hoa NB, Tiemersma EW, Sy DN, Nhung NV, Vree M, Borgdorff MW, Cobelens FG.

Trop Med Int Health. 2011 Oct;16(10):1260-7. doi: 10.1111/j.1365-3156.2011.02823.x. Epub 2011 Jun 22.

37.

Diagnosis and treatment of tuberculosis in the private sector, Vietnam.

Hoa NB, Cobelens FG, Sy DN, Nhung NV, Borgdorff MW, Tiemersma EW.

Emerg Infect Dis. 2011 Mar;17(3):562-4. doi: 10.3201/eid1703.101468. No abstract available.

38.

Risk of travelling to the country of origin for tuberculosis among immigrants living in a low-incidence country.

Kik SV, Mensen M, Beltman M, Gijsberts M, van Ameijden EJ, Cobelens FG, Erkens C, Borgdorff MW, Verver S.

Int J Tuberc Lung Dis. 2011 Jan;15(1):38-43.

PMID:
21276294
39.

Household expenditure and tuberculosis prevalence in VietNam: prediction by a set of household indicators.

Hoa NB, Tiemersma EW, Sy DN, Nhung NV, Gebhard A, Borgdorff MW, Cobelens FG.

Int J Tuberc Lung Dis. 2011 Jan;15(1):32-7.

PMID:
21276293
40.

Operational research for improved tuberculosis control: the scope, the needs and the way forward.

Lienhardt C, Cobelens FG.

Int J Tuberc Lung Dis. 2011 Jan;15(1):6-13.

PMID:
21276290
41.

Rates of anti-tuberculosis drug resistance in Kampala-Uganda are low and not associated with HIV infection.

Lukoye D, Cobelens FG, Ezati N, Kirimunda S, Adatu FE, Lule JK, Nuwaha F, Joloba ML.

PLoS One. 2011 Jan 10;6(1):e16130. doi: 10.1371/journal.pone.0016130.

42.

Measurement of exhaled nitric oxide as a potential screening tool for pulmonary tuberculosis.

Van Beek SC, Nhung NV, Sy DN, Sterk PJ, Tiemersma EW, Cobelens FG.

Int J Tuberc Lung Dis. 2011 Feb;15(2):185-92.

PMID:
21219679
43.

Effect of changing antiretroviral treatment eligibility criteria on patient load in Kampala, Uganda.

Konde-Lule J, Makumbi F, Pakker N, Muyinda A, Mubiru M, Cobelens FG.

AIDS Care. 2011 Jan;23(1):35-41. doi: 10.1080/09540121.2010.498869.

PMID:
20924829
44.

The Mycobacterium tuberculosis Beijing genotype does not affect tuberculosis treatment failure in Vietnam.

Buu TN, Huyen MN, van Soolingen D, Lan NT, Quy HT, Tiemersma EW, Borgdorff MW, Cobelens FG.

Clin Infect Dis. 2010 Oct 15;51(8):879-86. doi: 10.1086/656410.

PMID:
20836697
45.

Tuberculosis acquired outside of households, rural Vietnam.

Buu TN, van Soolingen D, Huyen MN, Lan NN, Quy HT, Tiemersma EW, Borgdorff MW, Cobelens FG.

Emerg Infect Dis. 2010 Sep;16(9):1466-8. doi: 10.3201/eid1609.100281.

46.

National anti-tuberculosis drug resistance study in Tanzania.

Chonde TM, Basra D, Mfinanga SG, Range N, Lwilla F, Shirima RP, van Deun A, Zignol M, Cobelens FG, Egwaga SM, van Leth F.

Int J Tuberc Lung Dis. 2010 Aug;14(8):967-72.

PMID:
20626940
47.

Validation of the GenoType MTBDRplus assay for diagnosis of multidrug resistant tuberculosis in South Vietnam.

Huyen MN, Tiemersma EW, Lan NT, Cobelens FG, Dung NH, Sy DN, Buu TN, Kremer K, Hang PT, Caws M, O'Brien R, van Soolingen D.

BMC Infect Dis. 2010 Jun 3;10:149. doi: 10.1186/1471-2334-10-149.

48.

National survey of tuberculosis prevalence in Viet Nam.

Hoa NB, Sy DN, Nhung NV, Tiemersma EW, Borgdorff MW, Cobelens FG.

Bull World Health Organ. 2010 Apr;88(4):273-80. doi: 10.2471/BLT.09.067801. Epub 2010 Feb 22. Erratum in: Bull World Health Organ. 2014 Aug 1;92(8):620.

49.

Decrease in risk of tuberculosis infection despite increase in tuberculosis among young adults in urban Vietnam.

Buu TN, Quy HT, Qui NC, Lan NT, Sy DN, Cobelens FG.

Int J Tuberc Lung Dis. 2010 Mar;14(3):289-95.

PMID:
20132619
50.

Mycobacterium tuberculosis genotype and case notification rates, rural Vietnam, 2003-2006.

Buu TN, Huyen MN, Lan NN, Quy HT, Hen NV, Zignol M, Borgdorff MW, van Soolingen D, Cobelens FG.

Emerg Infect Dis. 2009 Oct;15(10):1570-7. doi: 10.3201/eid1510.090170.

Supplemental Content

Loading ...
Support Center